Key result
Radionuclide LVEF monitoring during doxorubicin therapy remains essential to reduce CHF incidence and severity.
Design
Review
Authors
Loading...
Supports LVEF monitoring by radionuclide angiocardiography during doxorubicin; confirms prior recommendations but leaves open refinements with emerging cardioprotective strategies.
Current guidelines for LVEF monitoring using equilibrium radionuclide angiocardiography should be followed during doxorubicin therapy to reduce the incidence and severity of congestive heart failure.
Diwakar Jain (2000) conducted a review in Doxorubicin cardiotoxicity. Doxorubicin and other anthracycline derivatives was evaluated. Careful monitoring of left ventricular ejection fraction with radionuclide angiocardiography during doxorubicin therapy remains essential to reduce the incidence and severity of congestive heart failure.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: